← FDA DRUG APPROVALS

FDA NDA · NDA019680

DEPAKOTE SPRINKLES

divalproex sodium

Sponsor: ABBVIE

APPLICATION
NDA019680
TYPE
NDA
ORIGINAL APPROVAL
1989-09-12
LATEST ACTION
2026-03-31
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Prescription

Products

DEPAKOTE · ReferencePrescription
DIVALPROEX SODIUM EQ 125MG VALPROIC ACID · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2026-03-31Labeling · Supplement 60 · standardLetterAP
2025-05-01Labeling · Supplement 57 · standardLetterAP
2025-01-23Labeling · Supplement 56 · standardLabelAP
2024-03-18Labeling · Supplement 55 · standardLetterAP
2023-02-24Labeling · Supplement 53 · standardLetterAP
2021-11-30Labeling · Supplement 52 · standardLetterAP
2021-02-10Labeling · Supplement 51 · standardLetterAP
2020-05-19Labeling · Supplement 50 · standardLetterAP
2019-11-22Labeling · Supplement 49 · standardLetterAP
2019-02-21Labeling · Supplement 48 · standardLetterAP
2018-03-06Labeling · Supplement 47 · standardLetterAP
2017-10-05Labeling · Supplement 46 · standardLetterAP
2017-03-06Labeling · Supplement 45 · standardLabelAP
2016-11-02Labeling · Supplement 44 · standardLetterAP
2016-02-18Labeling · Supplement 43 · standardLetterAP
2015-09-23Labeling · Supplement 42 · standardLetterAP
2015-03-13Labeling · Supplement 41 · standardLetterAP
2015-01-07Labeling · Supplement 38 · standardLetterAP
2014-11-20Labeling · Supplement 37 · standardLetterAP
2014-08-20Labeling · Supplement 40 · standardLetterAP
2014-06-20Labeling · Supplement 33 · unknownLabelAP
2014-06-19Labeling · Supplement 28 · standardLabelAP
2014-06-09Labeling · Supplement 39 · standardLabelAP
2013-07-31Labeling · Supplement 35 · standardLetterAP
2013-06-14Labeling · Supplement 36 · standardLabelAP
2013-02-27Labeling · Supplement 34 · standardLabelAP
2011-10-07Labeling · Supplement 27 · standardLabelAP
2011-10-07Labeling · Supplement 25 · standardLetterAP
2011-10-07Labeling · Supplement 31 · unknownLetterAP
2011-10-07Labeling · Supplement 29 · unknownLabelAP
2009-04-23Labeling · Supplement 26 · 901 requiredLabelAP
2008-03-24Efficacy · Supplement 24 · priorityAP
2006-12-19Labeling · Supplement 21 · standardLetterAP
2006-10-13Labeling · Supplement 22 · standardLetterAP
2006-01-11Labeling · Supplement 19 · standardLabelAP
2002-12-12Labeling · Supplement 15 · standardLetterAP
2002-11-05Manufacturing (CMC) · Supplement 16 · standardAP
2000-06-19Labeling · Supplement 14 · standardAP
1998-05-08Manufacturing (CMC) · Supplement 13 · standardAP
1996-12-02Manufacturing (CMC) · Supplement 11 · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →